322 related articles for article (PubMed ID: 1377194)
1. Treatment of myelodysplastic syndromes with hematopoietic growth factors.
Ganser A; Hoelzer D
Hematol Oncol Clin North Am; 1992 Jun; 6(3):633-53. PubMed ID: 1377194
[TBL] [Abstract][Full Text] [Related]
2. Clinical use of hematopoietic growth factors in the myelodysplastic syndromes.
Ganser A; Hoelzer D
Semin Hematol; 1996 Jul; 33(3):186-95. PubMed ID: 8819229
[No Abstract] [Full Text] [Related]
3. [Clinical use of hematopoietic growth factors].
Robak T
Pol Tyg Lek; 1992 Apr 20-27; 47(16-17):365-8. PubMed ID: 1279638
[No Abstract] [Full Text] [Related]
4. Treatment of myelodysplastic syndromes with hemopoietic growth factors.
Greenberg PL
Semin Oncol; 1992 Feb; 19(1):106-14. PubMed ID: 1371018
[No Abstract] [Full Text] [Related]
5. Clinical use of recombinant human hematopoietic growth factors (GM-CSF, IL-3, EPO) in patients with myelodysplastic syndrome.
Herrmann F; Mertelsmann R; Lindemann A; Ottmann OG; Seipelt G; Oster W; Hoelzer D; Ganser A
Biotechnol Ther; 1991; 2(3-4):299-311. PubMed ID: 1845132
[TBL] [Abstract][Full Text] [Related]
6. The role of haematopoietic growth factors in the treatment of myelodysplastic syndromes.
Rossi Ferrini P; Santini V; Ciolli S; Grossi A; Leoni F; Rafanelli D; Vannucchi AM
Hematol Oncol; 1993; 11 Suppl 1():32-5. PubMed ID: 7683622
[No Abstract] [Full Text] [Related]
7. [Current status of the clinical application of hematopoietic growth factors in oncology].
Karthaus M; Ganser A
Ther Umsch; 1996 Nov; 53(11):863-73. PubMed ID: 8984692
[TBL] [Abstract][Full Text] [Related]
8. The role of hematopoietic growth factors in the treatment of neoplastic diseases.
St Onge J; Jacobson RJ
Semin Hematol; 1992 Jul; 29(3 Suppl 2):53-63. PubMed ID: 1380737
[No Abstract] [Full Text] [Related]
9. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L).
Bruserud O; Foss B; Petersen H
Eur Cytokine Netw; 2001; 12(2):231-8. PubMed ID: 11399510
[TBL] [Abstract][Full Text] [Related]
10. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
[TBL] [Abstract][Full Text] [Related]
11. c-kit ligand augments granulocyte-macrophage colony growth from patients with 5q- syndrome.
Rosenfeld CS; Nemunaitis J; Sherer CR; Zeigler ZR; Shadduck RK
Stem Cells; 1993 Nov; 11(6):562-7. PubMed ID: 7509225
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes.
Kasper C; Zahner J; Sayer HG
J Cancer Res Clin Oncol; 2002 Sep; 128(9):497-502. PubMed ID: 12242514
[TBL] [Abstract][Full Text] [Related]
13. [Hematopoietic growth factors in primary and therapy-related bone marrow insufficiency].
Hansen B; Hippe E; Jacobsen GK; Johnsen HE
Ugeskr Laeger; 1992 Jun; 154(24):1697-702. PubMed ID: 1378668
[TBL] [Abstract][Full Text] [Related]
14. In vitro enhancement of erythropoiesis by steel factor in Diamond-Blackfan anemia and treatment of other congenital cytopenias with recombinant interleukin 3/granulocyte-macrophage colony stimulating factor.
Sieff C; Guinan E
Stem Cells; 1993 Jul; 11 Suppl 2():113-22. PubMed ID: 7691316
[TBL] [Abstract][Full Text] [Related]
15. The use of haemopoietic growth factors in the treatment of myelodysplastic syndromes.
Greenberg PL; Negrin R; Nagler A
Cancer Surv; 1990; 9(1):199-212. PubMed ID: 2276114
[TBL] [Abstract][Full Text] [Related]
16. [Clinical application of hematopoietic growth factor (IL-3, G-CSF, GM-CSF, and EPO)].
Motoyoshi K
Nihon Rinsho; 1992 Aug; 50(8):1967-72. PubMed ID: 1279240
[TBL] [Abstract][Full Text] [Related]
17. Treatment of myelodysplastic syndromes with cytokines and cytotoxic drugs.
Ganser A; Seipelt G; Eder M; Geissler G; Ottmann OG; Hess U; Hoelzer D
Semin Oncol; 1992 Apr; 19(2 Suppl 4):95-101. PubMed ID: 1372766
[TBL] [Abstract][Full Text] [Related]
18. Increase in peripheral blood megakaryocyte progenitors following cancer therapy with high-dose cyclophosphamide and hematopoietic growth factors.
Siena S; Bregni M; Bonsi L; Sklenar I; Bagnara GP; Bonadonna G; Gianni AM
Exp Hematol; 1993 Nov; 21(12):1583-90. PubMed ID: 7691640
[TBL] [Abstract][Full Text] [Related]
19. Haematopoietic growth factors in the treatment of myelodysplastic syndromes.
Cazzola M
Forum (Genova); 1999; 9(1):49-57. PubMed ID: 10101210
[TBL] [Abstract][Full Text] [Related]
20. [GM-CSF and G-CSF: cytokines in clinical application].
Ruef C; Coleman DL
Schweiz Med Wochenschr; 1991 Mar; 121(12):397-412. PubMed ID: 1709294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
